Journal Article
Efficacy and safety of tocilizumab in severe COVID-19 patients: a single-centre retrospective cohort study
Campochiaro, C; Della-Torre, E; Cavalli, G; De Luca, G; Ripa, M; Boffini, N; Tomelleri, A; Baldissera, E; Rovere-Querini, P; Ruggeri, A; Monti, G; De Cobelli, F; Zangrillo, A; Tresoldi, M; Castagna, A; Dagna, L; Group, TRS
European Journal of Internal Medicine
ISSN: 0953-6205
EISSN: 1879-0828
Tocilizumab (TCZ), a humanized monoclonal antibody targeting the interleukin-6 (IL-6) receptor, has been proposed for the treatment of COVID-19 patients; however, limited data are available on the safety and efficacy.
Antibodies, Monoclonal, Humanized; Antiviral Agents; Receptors, Interleukin-6; tocilizumab; I031V2H011; Index Medicus; COVID-19; Coronavirus; Efficacy; Interleukin-6; Betacoronavirus -- isolation & purification; Outcome and Process Assessment, Health Care; Middle Aged; Antiviral Agents -- adverse effects; Betacoronavirus -- drug effects; SARS-CoV-2; Italy -- epidemiology; Retrospective Studies; Coronavirus Infections -- therapy; Pandemics; Receptors, Interleukin-6 -- antagonists & inhibitors; Respiratory Insufficiency -- etiology; Antibodies, Monoclonal, Humanized -- administration & dosage; Pneumonia, Viral -- therapy; Antibodies, Monoclonal, Humanized -- adverse effects; Pneumonia, Viral -- diagnosis; Coronavirus Infections -- mortality; Pneumonia, Viral -- blood; Coronavirus Infections -- blood; Pneumonia, Viral -- mortality; Pneumonia, Viral -- etiology; Respiratory Insufficiency -- therapy; Oxygen Inhalation Therapy -- methods; Coronavirus Infections -- physiopathology; Pneumonia, Viral -- drug therapy; Pneumonia, Viral -- physiopathology
